论文部分内容阅读
最近几年,高血压治疗领域缺乏轰动性的大型临床试验报道,抗高血压新药的研发也陷入停顿状态。但是专家们并不寂寞,他们总结或反思过去数十年高血压防治工作中的经验与教训,倡导优化治疗、修订临床指南。例如,2009年欧洲高血压指南发表了再评价版[1],2011年中国、英国和南非等都更新了高血压防治指南[2-4],美国预防、检测、评估与治疗高血压全国联合委员会第8次报告(the 8th report of the Joint National committee on prevention,detection,evaluation,and treatment of high blood pressure,JNC8)的撰写也进入收官阶段。笔者一直关注这些新指南和国际会议上的相关报告,因为从中可以看到高血压防治工作的新动向和新思路,进而指导我们的临床实践。
In recent years, the lack of a sensational large-scale clinical trial in the field of hypertension treatment reports that the development of new anti-hypertensive drugs has also come to a standstill. However, experts are not lonely. They summed up or reflected on the experiences and lessons learned in the prevention and treatment of hypertension in the past decades, advocating optimal treatment and revising clinical guidelines. For example, the 2009 European Hypertension Guide published a re-evaluation version [1]. In 2011, China, the United Kingdom and South Africa updated their guidelines for the prevention and treatment of hypertension [2-4]. The United States National Committee for the Prevention, Testing, Evaluation and Treatment of Hypertension The writing of the 8th report of the Joint National committee on prevention, detection, evaluation, and treatment of high blood pressure, JNC8 also came to a close. I have been following these new guidelines and related reports at international conferences because I can see the new trends and new ideas in the prevention and treatment of hypertension, which in turn guide our clinical practice.